• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

    4.680 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Aptevo Therapeutics Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
    Via ACCESS Newswire
    News headline image
    Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
    Via ACCESS Newswire
    News headline image
    Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update
    Via ACCESS Newswire
    News headline image
    Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
    Via ACCESS Newswire
    News headline image
    TOMI Environmental Solutions (NASDAQ: TOMZ): The Next Era of Disinfection Technology – More Stocks Inside
    Via AB Newswire
    News headline image
    Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
    Via ACCESS Newswire
    News headline image
    Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESS Newswire
    News headline image
    Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
    Via ACCESS Newswire
    News headline image
    Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
    Via ACCESS Newswire
    News headline image
    Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules
    Via ACCESS Newswire
    News headline image
    Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
    Via ACCESS Newswire
    News headline image
    Aptevo Participating in the BIO International Convention
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    Via ACCESS Newswire
    News headline image
    Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
    Via ACCESS Newswire
    News headline image
    $2 Stocks to Watch: PNPN.V, TIVC, APVO, OSRH, PRSO Biotech Breakthroughs, MedTech Momentum Metallic Metals Power Play & Signal Innovation
    Via AB Newswire
    Topics Intellectual Property
    News headline image
    Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
    Via ACCESS Newswire
    News headline image
    RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
    Via ACCESS Newswire
    News headline image
    Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
    Via ACCESS Newswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.